BACE1 and Alzheimer disease: Although further validation of AO2 in vivo and its effect on Aβ production is required to ensure the applicability of this molecule towards the clinical benefits in mitigating AD, we believe that partial inhibition of BACE1 protein levels achieved in this work could be used as a potential preventative strategy for people at high-risk of developing AD.